September 8, 2022 02:13 PM EDT

Teva fires back at GSK again over potential 'skinny' label SCOTUS case

Paul Schloesser

Associate Editor

Teva on Wednesday fired back at GSK after the UK-based drugmaker sought to squash Teva’s attempt to get its “skinny” label case overturned by the US Supreme Court.

Teva filed a reply to GSK on Wednesday, slamming the firm’s claims around these label carve-outs, which generic drugmakers use frequently to get competition on the market before all the patented indications of the reference product can be challenged.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Teva fires back at GSK again over potential 'skinny' label SCOTUS case

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Te­va fires back at GSK again over po­ten­tial 'skin­ny' la­bel SCO­TUS case

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Teva fires back at GSK again over potential 'skinny' label SCOTUS case

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape